Bendit (Bendamustine hydrochloride ) is approved to treat:
- B-cell non-Hodgkin lymphoma (NHL) in patients whose disease has not gotten better with other chemotherapy or has recurred (come back).
- Chronic lymphocytic leukemia (CLL).
100mg Ing (Single Dose Vial )
Dose for Chronic Lymphocytic Leukemia
Recommended dose: 100 mg/m2 administered intravenously on days 1 and 2 of a 28 day cycle, up to 6 cycles, it is intended for administration as an intravenous infusion over 30 minutes
Dose for non-Hodgkin’s Lymphoma
Recommended dose: 120 mg/m2 intravenously on days 1 and 2 of a 21 day cycle for up to 8 cycles. Bendamustine is intended for administration as an intravenous infusion over 60 minutes
Bendit is a prescription drug and should be used under proper medical guidance and advice
This medicine is to be taken strictly under Supervision of Medical Oncologist Only